Key facts
- Notable investors include Metaplanet Holdings, Entrepreneurs First.
- Helicon has filed 1 Form D with the SEC, most recently Apr 2026 ($20K sold to 1 investors).
- Status: Privately Held (backing).
Investors
2Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Helicon
Create free account
No card required
Funding rounds
1 roundsJan 2025Early Stage VC—▮
About Helicon
Developer of ribonucleic acid medicine intended to prevent neurodegenerative diseases. The company is currently operating in Stealth Mode.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Ireland
- Website
- helicontx.com/
- Ownership
- Privately Held (backing)
PA Mark — not yet priced
Helicon doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Helicon shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
No fund marks yet
No SEC-registered fund has reported a fair-value mark on Helicon in its N-PORT filings yet. We sweep new filings monthly.
Pro members can request priority coverage with a 48-hour turnaround.